Answers are grounded in this paper and cite their sources.
Retrospective study demonstrates robust hemolytic control and high transfusion independence in paroxysmal nocturnal hemoglobinuria, indicating oral iptacopan offers strong real-world efficacy.
To evaluate the real-world efficacy and safety of iptacopan in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) in China. This retrospective study included data collected from patients who commenced iptacopan treatment for PNH. Changes in clinical and laboratory indicators were examined after 1, 3, and 6 months and during the subsequent follow-up. A total of 54 patients were enrolled, including 17 (31.5%) females, with a median age of 38 years (range, 21–82). Before iptacopan treatment, 20 cases (37%) were transfusion-dependent. During a median follow-up of 10 months (range, 6 − 18), 53 (98.1%) patients had at least one lactate dehydrogenase ≤ 1.5 times the upper limit of normal and 46 (85.2%) achieved hemoglobin levels ≥ 120 g/L. All transfusion-dependent patients at baseline became transfusion-independent. No significant differences were noted in hemolytic parameters between classic PNH group and aplastic anemia/PNH group. Breakthrough hemolysis occurred in 7.4%. The most common adverse events were headache (13%) and upper respiratory tract infection (13%). No new thrombosis or microvascular events, extravascular hemolysis, and breakthrough infections by Neisseria meningitidis or Streptococcus pneumoniae were noticed. Iptacopan showed sustained hemolytic control, significant hemoglobin improvement, and favorable safety in Chinese PNH patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: